loading
前日終値:
$11.84
開ける:
$11.93
24時間の取引高:
544.79K
Relative Volume:
0.58
時価総額:
$656.43M
収益:
$59,000
当期純損益:
$-84.74M
株価収益率:
-2.1023
EPS:
-5.8222
ネットキャッシュフロー:
$-59.69M
1週間 パフォーマンス:
-8.86%
1か月 パフォーマンス:
-23.83%
6か月 パフォーマンス:
-8.31%
1年 パフォーマンス:
-11.94%
1日の値動き範囲:
Value
$11.70
$12.35
1週間の範囲:
Value
$11.58
$13.82
52週間の値動き範囲:
Value
$11.58
$24.27

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Name
名前
Avalo Therapeutics Inc
Name
セクター
Healthcare (1051)
Name
電話
410-522-8707
Name
住所
1500 LIBERTY RIDGE DRIVE, WAYNE
Name
職員
33
Name
Twitter
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
AVTX's Discussions on Twitter

Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AVTX icon
AVTX
Avalo Therapeutics Inc
12.24 656.43M 59,000 -84.74M -59.69M -5.8222
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
508.15 128.80B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
238.82 95.35B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
799.63 82.33B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
851.39 53.54B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
373.90 42.30B 5.76B 514.49M 1.10B 4.4813

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-07-06 開始されました Leerink Partners Outperform
2026-06-12 開始されました BofA Securities Buy
2026-04-09 開始されました Wolfe Research Outperform
2026-04-06 開始されました Citizens Mkt Outperform
2026-02-02 開始されました Guggenheim Buy
2025-12-18 開始されました Mizuho Outperform
2025-09-17 繰り返されました H.C. Wainwright Buy
2025-09-05 開始されました TD Cowen Buy
2025-08-15 開始されました Cantor Fitzgerald Overweight
2025-06-02 再開されました H.C. Wainwright Buy
2025-03-25 開始されました Jefferies Buy
2025-03-25 開始されました Stifel Buy
2025-02-28 開始されました Piper Sandler Overweight
2025-02-21 開始されました Wedbush Outperform
2024-12-19 開始されました BTIG Research Buy
2024-10-24 開始されました H.C. Wainwright Neutral
2024-04-16 アップグレード Oppenheimer Perform → Outperform
2021-09-24 開始されました RBC Capital Mkts Outperform
すべてを表示

Avalo Therapeutics Inc (AVTX) 最新ニュース

pulisher
Oct 02, 2026

In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan

Oct 02, 2026
pulisher
Oct 02, 2026

1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan

Oct 02, 2026
pulisher
Oct 02, 2026

In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan

Oct 02, 2026
pulisher
Sep 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Sep 29, 2026
pulisher
Sep 29, 2026

Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan

Sep 29, 2026
pulisher
Sep 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 29, 2026
pulisher
Sep 18, 2026

Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media

Sep 18, 2026
pulisher
Sep 18, 2026

Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan

Sep 18, 2026
pulisher
Sep 13, 2026

AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan

Sep 13, 2026
pulisher
Sep 11, 2026

Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan

Sep 11, 2026
pulisher
Sep 10, 2026

Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 06, 2026

(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 04, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Sep 04, 2026
pulisher
Sep 04, 2026

Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha

Sep 04, 2026
pulisher
Sep 04, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Six new hires get options to buy 78,000 Avalo shares - Stock Titan

Sep 04, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Nigeria

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Canada

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India

Sep 03, 2026
pulisher
Sep 03, 2026

Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com UK

Sep 03, 2026
pulisher
Sep 02, 2026

Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada

Sep 02, 2026
pulisher
Sep 02, 2026

Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com

Sep 02, 2026
pulisher
Sep 02, 2026

Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Australia

Sep 02, 2026
pulisher
Sep 01, 2026

Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan

Sep 01, 2026
pulisher
Aug 28, 2026

Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026
pulisher
Aug 27, 2026

How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily

Aug 27, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria

Aug 25, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India

Aug 25, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria

Aug 25, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com India

Aug 25, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com UK

Aug 25, 2026
pulisher
Aug 25, 2026

Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - investing.com

Aug 25, 2026
pulisher
Aug 23, 2026

AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com

Aug 23, 2026
pulisher
Aug 22, 2026

Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView

Aug 22, 2026
pulisher
Aug 20, 2026

Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn

Aug 20, 2026
pulisher
Aug 19, 2026

Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media

Aug 19, 2026
pulisher
Aug 19, 2026

Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan

Aug 19, 2026
pulisher
Aug 19, 2026

Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com

Aug 19, 2026
pulisher
Aug 19, 2026

Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan

Aug 19, 2026
pulisher
Aug 19, 2026

Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn

Aug 19, 2026
pulisher
Aug 19, 2026

Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media

Aug 19, 2026
pulisher
Aug 18, 2026

Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan

Aug 18, 2026
pulisher
Aug 17, 2026

Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan

Aug 17, 2026

Avalo Therapeutics Inc (AVTX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Avalo Therapeutics Inc (AVTX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Sullivan Christopher Ryan
Chief Financial Officer
Sep 16 '26
Sale
16.33
12,394
202,437
39,900
Sullivan Christopher Ryan
Chief Financial Officer
Sep 10 '26
Option Exercise
8.04
10,185
81,887
50,085
Sullivan Christopher Ryan
Chief Financial Officer
Sep 10 '26
Sale
17.62
10,185
179,457
39,900
Doyle Mittie
Chief Medical Officer
Aug 28 '26
Sale
20.00
679
13,580
51,776
Doyle Mittie
Chief Medical Officer
Aug 28 '26
Option Exercise
8.04
679
5,459
52,455
Sullivan Christopher Ryan
Chief Financial Officer
Aug 18 '26
Option Exercise
9.88
31,031
306,586
70,931
Sullivan Christopher Ryan
Chief Financial Officer
Aug 18 '26
Sale
20.05
31,031
622,324
39,900
CHRISTOPHER RYAN SULLIVAN
Officer
Aug 18 '26
Proposed Sale
20.05
31,031
622,221
0
CHRISTOPHER RYAN SULLIVAN
Officer
Aug 17 '26
Proposed Sale
19.59
70,709
1,385,189
0
Sullivan Christopher Ryan
Chief Financial Officer
Aug 17 '26
Option Exercise
9.88
40,821
403,311
81,594
$6.375
price up icon 3.32%
$3.585
price up icon 14.54%
$14.84
price down icon 0.80%
$4.665
price up icon 2.53%
$8.88
price down icon 2.09%
$3.585
price down icon 2.32%
大文字化:     |  ボリューム (24 時間):